Skip to Content

BetterLife Pharma Inc BETRF

Morningstar Rating
$0.09 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BETRF is trading at a 473% premium.
Price
$0.09
Fair Value
$2.29
Uncertainty
Extreme
1-Star Price
$3.49
5-Star Price
$5.87
Economic Moat
Blj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BETRF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.09
Day Range
$0.080.09
52-Week Range
$0.030.10
Bid/Ask
$0.06 / $0.09
Market Cap
$11.09 Mil
Volume/Avg
23,849 / 23,190

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
4

Valuation

Metric
BETRF
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BETRF
Quick Ratio
0.01
Current Ratio
0.05
Interest Coverage
−55.95
Quick Ratio
BETRF

Profitability

Metric
BETRF
Return on Assets (Normalized)
−697.57%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
BETRF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
JwwnsvmqqVgp$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
LnqvgymbCwrmwwr$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
DdvjcnjQhnzg$116.0 Bil
Moderna Inc
MRNA
FksnzmlkNmx$51.1 Bil
argenx SE ADR
ARGX
NpnfwfgNszn$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
QshdngnxPhyscmm$21.0 Bil
BioNTech SE ADR
BNTX
LbhsbpbBcqxn$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
QbyscqjcSlbpz$15.9 Bil
United Therapeutics Corp
UTHR
ZnngrfppJcxv$14.0 Bil
Incyte Corp
INCY
GgqbfvzYvprprx$12.5 Bil

Sponsor Center